Why Cg Oncology Stock Rocketed 7% Higher Today
Highly specialized biotech CG Oncology (NASDAQ: CGON) was the subject of a new research report Wednesday, and its bullish tone helped lift the company's share price. This improved by more than 7% on the day, easily beating the 0.6% advance of the bellwether S&P 500 (SNPINDEX: ^GSPC).
That publication marked the initiation of coverage on CG Oncology stock by veteran researcher Guggenheim, in the person of prognosticator Brad Canino. He rated the company's shares a buy at a price target of $90 per share, which is more than double their latest closing price.
Image source: Getty Images.
Source Fool.com
